A Real-World Study on Extranodal Lymphoma

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06573099

Enrollment

5000

Registered

2024-08-27

Start date

2024-09-01

Completion date

2029-09-01

Last updated

2024-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diffuse Large B Cell Lymphoma, Extranodal Lymphoma, Lymphoma, Lymphoma, B-Cell, Lymphoma, Non-Hodgkin

Keywords

LYMPHOMA, EXTRANODAL, DLBCL

Brief summary

The aim of this study is to prospectively collect clinical information on patients with extranodal lymphoma, and to explore the best therapeutic strategies in the real-world population.

Detailed description

Lymphoma is a common hematological malignancy. Many different pathologic types of lymphoma can originate in extranodal organs or be associated with extranodal organ involvement. For lymphoma with extranodal involvement, conventional regimens often cannot provide satisfactory results for patients. This study aims to prospectively collect clinical information on patients with extranodal DLBCL, including the distribution of involved sites, clinical and molecular characteristics of different lymphoma subtypes, clinical treatment protocols, and prognosis, to explore the the best therapeutic strategies in the real-world population.

Interventions

OTHERNo interventions need to be specified for this study

No interventions need to be specified for this study

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

1. Age ≥ 18 years (including 18 years old). 2. Patients newly diagnosed with non-Hodgkin lymphoma with extranodal involvement, whether it is primary, secondary, or cannot be determined. 3. Patients who have received systematic clinical treatment. 4. Patients with measurable lesions, at least containing one effective evaluation of efficacy.

Exclusion criteria

1. Patients who only receive supportive treatment. 2. Patients who cannot obtain effective evaluation data of efficacy.

Design outcomes

Primary

Measure	Time frame	Description
Progression Free Survival (PFS)	Baseline up to data cut-off (up to approximately 1 year)	Progression-Free Survival (PFS) will be defined from the date of starting therapy and the date of disease progression, relapse or death from any cause.

Secondary

Measure	Time frame	Description
Overall Survival (OS)	Baseline up to data cut-off (up to approximately 1 year)	Overall Survival (OS) will be defined from the start date of therapy to the date of death from any cause.

Contacts

Primary ContactWeili Zhao, MD, PhD

zwl_trial@163.com+862164370045

Backup ContactPengpeng Xu, MD

pengpeng_xu@126.com+862164370045

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026